| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
75,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,229 |
48,805 |
236,705 |
576,095 |
| Total Sell Value |
$1,027,488 |
$2,098,369 |
$9,481,770 |
$22,449,223 |
| Total People Sold |
3 |
4 |
7 |
10 |
| Total Sell Transactions |
3 |
6 |
11 |
22 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pimstone Simon N. |
CEO |
• • – |
2019-09-20 |
4 |
S |
$9.51 |
$98,856 |
D/D |
(10,395) |
258,122 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2019-09-20 |
4 |
S |
$9.39 |
$48,884 |
D/D |
(5,206) |
118,955 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2019-09-19 |
4 |
S |
$9.27 |
$70,452 |
D/D |
(7,600) |
124,161 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2019-09-18 |
4 |
S |
$9.28 |
$40,535 |
D/D |
(4,368) |
131,761 |
|
- |
|
| Pimstone Simon N. |
CEO |
• • – |
2019-09-17 |
4 |
D |
$9.44 |
$162,651 |
D/D |
(17,230) |
268,517 |
|
- |
|
| Pimstone Simon N. |
CEO |
• • – |
2019-09-17 |
4 |
OE |
$3.07 |
$203,381 |
D/D |
57,612 |
272,209 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2019-09-17 |
4 |
S |
$9.32 |
$47,243 |
D/D |
(5,069) |
136,129 |
|
- |
|
| Azab Mohammad |
Director |
– • – |
2019-09-13 |
4 |
S |
$9.31 |
$214 |
D/D |
(23) |
57,561 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2019-09-12 |
4 |
D |
$9.38 |
$90,508 |
D/D |
(9,649) |
141,198 |
|
- |
|
| Holler Frank A |
Director |
– • – |
2019-09-12 |
4 |
OE |
$3.00 |
$98,052 |
D/D |
31,892 |
148,979 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2019-09-12 |
4 |
D |
$9.38 |
$17,522 |
D/D |
(1,868) |
10,196 |
|
- |
|
| Robin Sherrington |
EVP, Strategy & Innovation |
• – – |
2019-09-12 |
4 |
OE |
$3.07 |
$18,948 |
D/D |
6,172 |
12,064 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2019-05-21 |
4 |
OE |
$3.21 |
$6,603 |
D/D |
2,057 |
64,569 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2019-03-19 |
4 |
OE |
$3.38 |
$69,547 |
I/I |
20,576 |
50,924 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2019-03-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
17,337 |
114,403 |
|
- |
|
| Hayden Michael R |
Director |
– • – |
2019-03-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
24,045 |
107,562 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2018-12-21 |
4 |
GD |
$0.00 |
$0 |
D/D |
5,000 |
62,512 |
|
- |
|
| Patou Gary |
Director |
– • – |
2018-12-14 |
4 |
OE |
$3.07 |
$6,315 |
D/D |
2,057 |
19,459 |
|
- |
|
| Cohen Charles J. |
VP, Biology |
• – – |
2018-12-11 |
4 |
D |
$7.00 |
$11,508 |
D/D |
(1,644) |
6,550 |
|
- |
|
| Cohen Charles J. |
VP, Biology |
• – – |
2018-12-11 |
4 |
OE |
$3.07 |
$12,633 |
D/D |
4,115 |
8,194 |
|
- |
|
| Azab Mohammad |
Director |
– • – |
2018-12-06 |
4 |
OE |
$3.07 |
$9,474 |
D/D |
3,086 |
57,584 |
|
- |
|
| Tarnow Michael M |
Director |
– • – |
2018-06-21 |
4 |
OE |
$3.07 |
$42,354 |
D/D |
12,345 |
67,512 |
|
- |
|
| Azab Mohammad |
Director |
– • – |
2018-06-21 |
4 |
OE |
$3.70 |
$38,066 |
D/D |
10,288 |
54,498 |
|
- |
|
| Patou Gary |
Director |
– • – |
2018-06-14 |
4 |
D |
$8.30 |
$23,705 |
D/D |
(2,856) |
17,402 |
|
- |
|
| Patou Gary |
Director |
– • – |
2018-06-14 |
4 |
OE |
$3.70 |
$30,451 |
D/D |
8,230 |
20,258 |
|
- |
|
231 Records found
|
|
Page 5 of 10 |
|
|
